Danieli Andrade
A5091027078- Systemic Lupus Erythematosus Research
- Platelet Disorders and Treatments
- Systemic Sclerosis and Related Diseases
- Renal Diseases and Glomerulopathies
- Heparin-Induced Thrombocytopenia and Thrombosis
- Liver Diseases and Immunity
- Diabetes and associated disorders
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Long-Term Effects of COVID-19
- SARS-CoV-2 and COVID-19 Research
- Parvovirus B19 Infection Studies
- Blood disorders and treatments
- COVID-19 Clinical Research Studies
- Pregnancy and Medication Impact
- Hepatitis C virus research
- Reproductive System and Pregnancy
- Eosinophilic Disorders and Syndromes
- Liver Disease Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Vasculitis and related conditions
- Venous Thromboembolism Diagnosis and Management
- Atherosclerosis and Cardiovascular Diseases
- Intensive Care Unit Cognitive Disorders
Universidade de São Paulo
2016-2025
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
2012-2025
Instituto Ecuatoriano de Enfermedades Digestivas
2020-2024
University of Turin
2019-2024
Collegio Carlo Alberto
2023
Chr. Hansen (Denmark)
2023
Universidade Federal de São Paulo
2018-2021
AC Camargo Hospital
2020
Ospedale San Giovanni Bosco
2019
Cornell University
2014-2018
To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. This international multidisciplinary initiative included 4 phases: 1) Phase I, generation surveys literature review; 2) II, reduction modified Delphi nominal group technique exercises; 3) III, definition, further guidance real-world patient scenarios, weighting via consensus-based...
<h3>Objective</h3> To develop new antiphospholipid syndrome (APS) classification criteria with high specificity for use in observational studies and trials, jointly supported by the American College of Rheumatology (ACR) EULAR. <h3>Methods</h3> This international multidisciplinary initiative included four phases: (1) Phase I, generation surveys literature review; (2) II, reduction modified Delphi nominal group technique exercises; (3) III, definition, further guidance real-world patient...
Catastrophic antiphospholipid syndrome (CAPS) is characterized by histopathologic evidence of small vessel thrombosis, dysfunction multiple organs occurring over a short period time, and laboratory confirmation the presence antibodies (aPL). Treatment CAPS focuses on anticoagulation therapy removal aPL that promote thrombosis activating endothelial cells, monocytes, platelets. Studies in animal models support hypothesis more targeted intervention, such as complement inhibition, may be an...
Objective To determine the immunogenicity of third dose CoronaVac vaccine in a large population patients with autoimmune rheumatic diseases (ARD) and factors associated impaired response. Methods Adult ARD age-balanced/sex-balanced controls (control group, CG) previously vaccinated two doses received at D210 (6 months after second dose). The presence anti-SARS-CoV-2 S1/S2 IgG neutralising antibodies (NAb) was evaluated to vaccination (D210) 30 days later (D240). Patients controlled disease...
This study aimed to elucidate the presence, antigen specificities, and potential clinical associations of anti-neutrophil extracellular trap (anti-NET) antibodies in a multinational cohort antiphospholipid (aPL) antibody-positive patients who did not have lupus.
Objective To investigate whether an elevated interferon‐α (IFNα) level early in pregnancy is associated with poor outcomes and to examine the relationship of IFNα angiogenic imbalance. Methods Women were enrolled a longitudinal case–control study pregnant patients lupus. Serum samples obtained monthly throughout assayed for antiangiogenic factor soluble Flt‐1 proangiogenic placenta growth (PlGF). Each 28 systemic lupus erythematosus (SLE) outcome was matched SLE patient uncomplicated healthy...
Objective To describe the baseline characteristics of patients with positivity for antiphospholipid antibodies (aPLs) who were enrolled in an international registry, Antiphospholipid Syndrome (APS) Alliance Clinical Trials and International Networking (APS ACTION) clinical database repository, overall by laboratory subtypes. Methods The APS ACTION registry includes adults persistently had aPLs. We evaluated sociodemographic aPL‐related classification criteria “non‐criteria”) subgroups...
Long-lasting effects of COVID-19 may include cardiovascular, respiratory, skeletal muscle, metabolic, psychological disorders and persistent symptoms that can impair health-related quality life (HRQoL). We investigated the a home-based exercise training (HBET) programme on HRQoL outcomes in survivors severe/critical COVID-19.This was single-centre, single-blinded, parallel-group, randomised controlled trial. Fifty (5±1 months after intensive care unit discharge) were randomly allocated (1:1)...
Objective Although systemic lupus erythematosus ( SLE ) is the most common autoimmune disease associated with antiphospholipid antibodies aPL ), limited data exist regarding impact of on clinical phenotype ‐positive patients. The primary objective this study was to compare clinical, laboratory, and treatment characteristics patients those without SLE. Methods A secure web‐based capture system used store patient demographic ‐related laboratory characteristics. Inclusion criteria included...
To date, the only study that has assessed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 mRNA) vaccine in systemic lupus erythematosus (SLE) observed a moderate response, but sample size precluded an accurate analysis of effect individual drugs. Therefore, we evaluated immunogenicity inactivated SARS-CoV-2 (Sinovac-CoronaVac) and influence different medications SLE. Safety was also assessed.We conducted prospective controlled 232 SARS-CoV-2-naive SLE patients 58 controls who...
Objectives To describe the outcomes of pregnancies in antiphospholipid antibody (aPL)-positive patients since inception AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Registry. Methods We identified persistently aPL-positive recorded as ‘pregnant’ during prospective follow-up, defined ‘aPL-related outcome’ a composite of: (1) Preterm live delivery (PTLD) at or before 37th week due to pre-eclampsia (PEC), eclampsia, small-for-gestational age (SGA) and/or...
Our findings provide novel data regarding the impact of COVID-19 on submaximal and maximal cardiopulmonary responses to exercise. We showed that V̇o 2 kinetics is significantly impaired at both onset (on-transient) recovery phase (off-transient) exercise in these patients. Furthermore, our results suggest survivors severe may have a higher metabolic demand walking pace. These partly explain exertional intolerance frequently observed following COVID-19.
Abstract Objective To construct a humanized mouse model of systemic lupus erythematosus (SLE) that resembles the human disease in order to define pathophysiology and targets for treatments. Methods We infused peripheral blood mononuclear cells (PBMCs) from SLE patients into BALB‐ RAG‐2 −/− IL‐2Rγ double‐knockout (DKO) mice, which lack T cells, B natural killer cells. PBMCs 5 4 normal donors were intravenously/intraperitoneally at density 3–5 × 10 6 per animal nonirradiated 4–5‐week‐old mice....